Related Experiment Video

Updated: Mar 28, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

Saveri Bhattacharya1, Mark A Socinski2, Timothy F Burns3

  • 1University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Room 461, Pittsburgh, PA, 15232, USA. bhattacharyas3@upmc.edu.

Clinical and Translational Medicine
|December 16, 2015
PubMed

Insights

KRAS mutations are common in non-small cell lung cancer (NSCLC), leading to poor outcomes. Recent progress in targeting the RAS-RAF-MEK-ERK pathway offers new hope for treating KRAS-mutant NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS mutations are the most frequent driver mutations in non-small cell lung cancer (NSCLC).
  • These mutations are associated with a poor prognosis for patients.
  • Previous therapeutic strategies targeting KRAS mutations have largely been unsuccessful over the past two decades.

Purpose of the Study:

  • To review the recent advancements in understanding and targeting KRAS-mutant non-small cell lung cancer.
  • To highlight the therapeutic potential of targeting the RAS-RAF-MEK-ERK (MAPK) pathway.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of the molecular mechanisms underlying KRAS-mutant NSCLC.
  • Evaluation of emerging therapeutic strategies targeting the MAPK pathway.

Main Results:

  • Significant progress has been made in understanding the molecular landscape of KRAS-mutant NSCLC.
  • Targeting the RAS-RAF-MEK-ERK (MAPK) pathway has shown promise in preclinical and early clinical studies.
  • New therapeutic approaches are emerging, offering optimism for improved patient outcomes.

Conclusions:

  • Despite historical challenges, targeting KRAS-mutant NSCLC is becoming increasingly feasible.
  • The RAS-RAF-MEK-ERK (MAPK) pathway represents a critical target for novel therapies.
  • Continued research and development in this area hold promise for transforming the treatment of NSCLC.
Keywords:
KRAS mutant NSCLCMAPK pathwayTargeted therapy

More Related Videos

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

7.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K